Clinical Response to Apatinib Combined With Brain Radiotherapy in EGFR Wild-Type and ALK-Negative Lung Adenocarcinoma With Multiple Brain Metastases

Clinical Response to Apatinib Combined With Brain Radiotherapy in EGFR Wild-Type and ALK-Negative Lung Adenocarcinoma With Multiple Brain Metastases

Background: Brain radiotherapy is the standard treatment option for multiple brain metastases (BMs) from non-small cell lung cancer (NSCLC), especially in the absence of a driver mutation. However, the prognosis for such patients remains poor. Apatinib is a potent antiangiogenic compound directed at...

Full description

Bibliographic Details
Main Authors: Xiaofang Ying, Huali Liu, Mingwei Wang, Min Peng, Peng Ruan, Vivek Verma, Guang Han
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-04-01
Series:Frontiers in Oncology
Subjects:
apatinib
EGFR wild-type
ALK-negative
lung adenocarcinoma
brain metastases
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00517/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00517/full

Similar Items